Celldex Therapeutics Inc

CLDX remains in Stage 2 advancing within an intact long-term uptrend but is undergoing a sharp corrective pullback after a terminal blow-off top. Medium-term bias stays bullish as price holds above the rising 50-DMA and overall HH/HL structure. Short-term timing is unfavorable, with price below the 9- and 21-EMAs and momentum down, so we will stalk a pullback into the 50-DMA support zone for absorption before re-engaging.

• ↑Phase 2: 71% complete response at week 76 in CSU.
• ↑Cash position: $408M funds clinical trials through 2025.
• ↓Negative profitability factors indicate poor return generation.